These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 27090924)

  • 1. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
    Salehi S; Saljooghi ASh; Shiri A
    Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.
    Loza-Rosas SA; Vázquez-Salgado AM; Rivero KI; Negrón LJ; Delgado Y; Benjamín-Rivera JA; Vázquez-Maldonado AL; Parks TB; Munet-Colón C; Tinoco AD
    Inorg Chem; 2017 Jul; 56(14):7788-7802. PubMed ID: 28644630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
    Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
    Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of tridentate iron chelators: from desferrithiocin to ICL670.
    Nick H; Acklin P; Lattmann R; Buehlmayer P; Hauffe S; Schupp J; Alberti D
    Curr Med Chem; 2003 Jun; 10(12):1065-76. PubMed ID: 12678677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
    Messa E; Carturan S; Maffè C; Pautasso M; Bracco E; Roetto A; Messa F; Arruga F; Defilippi I; Rosso V; Zanone C; Rotolo A; Greco E; Pellegrino RM; Alberti D; Saglio G; Cilloni D
    Haematologica; 2010 Aug; 95(8):1308-16. PubMed ID: 20534700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
    Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
    World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1,3,5-triazine family.
    Sun D; Melman G; Letourneau NJ; Hays AM; Melman A
    Bioorg Med Chem Lett; 2010 Jan; 20(2):458-60. PubMed ID: 20005708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.
    Jansová H; Macháček M; Wang Q; Hašková P; Jirkovská A; Potůčková E; Kielar F; Franz KJ; Simůnek T
    Free Radic Biol Med; 2014 Sep; 74():210-21. PubMed ID: 24992833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
    Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
    Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICL670A: preclinical profile.
    Nick H; Wong A; Acklin P; Faller B; Jin Y; Lattmann R; Sergejew T; Hauffe S; Thomas H; Schnebli HP
    Adv Exp Med Biol; 2002; 509():185-203. PubMed ID: 12572995
    [No Abstract]   [Full Text] [Related]  

  • 11. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
    Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
    Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
    Kim JL; Lee DH; Na YJ; Kim BR; Jeong YA; Lee SI; Kang S; Joung SY; Lee SY; Oh SC; Min BW
    Tumour Biol; 2016 Jul; 37(7):9709-19. PubMed ID: 26803514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron chelation in the treatment of cancer: a new role for deferasirox?
    Bedford MR; Ford SJ; Horniblow RD; Iqbal TH; Tselepis C
    J Clin Pharmacol; 2013 Sep; 53(9):885-91. PubMed ID: 23740857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
    Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
    BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
    Al-Rousan RM; Rice KM; Katta A; Laurino J; Walker EM; Wu M; Triest WE; Blough ER
    Transl Res; 2011 Jun; 157(6):368-77. PubMed ID: 21575921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelators induce autophagic cell death in multiple myeloma cells.
    Pullarkat V; Meng Z; Donohue C; Yamamoto VN; Tomassetti S; Bhatia R; Krishnan A; Forman SJ; Synold TW
    Leuk Res; 2014 Aug; 38(8):988-96. PubMed ID: 24998390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
    Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
    Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferasirox-TAT(47-57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine.
    Goswami D; Vitorino HA; Alta RY; Silvestre DM; Nomura CS; Machini MT; Espósito BP
    Biometals; 2015 Oct; 28(5):869-77. PubMed ID: 26164834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chelation of thallium by combining deferasirox and desferrioxamine in rats.
    Saljooghi AS; Babaie M; Mendi FD; Zahmati M; Saljooghi ZS
    Toxicol Ind Health; 2016 Jan; 32(1):83-8. PubMed ID: 24021432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.